Canmerry (Guangdong) Biopharmaceutical Technology Co., Ltd., a subsidiary of Canada's CPI Pharmaceuticals, is a high-tech enterprise specializing in the research, development, and industrialization of highly active collagen biomaterials. Established on May 26, 2023, and located in the Southern Beauty Valley Industrial Park, Huangpu District, Guangzhou, the company is China's first enterprise to simultaneously possess qualifications in cosmetics, medical devices, pharmaceuticals, and U.S. FDA certification for the development and production of active collagen raw materials.

The company's Phase I project features a 4,000-square-meter GMP-standard production facility, equipped with internationally advanced production equipment and testing instruments. This setup supports the full-chain production of collagen raw materials, biotech skincare products, and high-value medical devices, ensuring high quality and safety of its products.

In September 2023, the company collaborated with the Guangzhou Development District Administrative Committee to establish the "Canmerry Biopharmaceutical Research Institute" and an Academician Workstation. It has assembled a high-level R&D team led by renowned domestic and international experts, focusing on technological research and product development in the biomedical field. The company has achieved several notable scientific breakthroughs, such as developing a bioactive hydrogel with both anti-inflammatory and antibacterial properties to address diabetic wound healing challenges, a bifunctional immunomodulatory hydrogel scaffold to promote spinal cord injury repair, and obesity treatment technology in collaboration with Columbia University.

Since its establishment two years ago, the company has achieved remarkable success. In February 2024, it completed the registration of the master file for bovine collagen raw materials. In September 2024, Canmerry was recognized as a "Guangdong Provincial Technology-based SME." In February 2025, the company obtained China's first pharmaceutical ex